Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CPG 7909 Plus Herceptin® in Patients With Metastatic Breast Cancer

Study:

A Phase 1/2 Open-Label, Multi-Center, Dose-Escalation Study of Subcutaneous CPG 7909 Plus Herceptin® in Patients With Metastatic Breast Cancer

Rationale:

n/a

Purpose:

The purpose of this study is to determine whether CPG 7909 in combination with Herceptin is safe and effective in the treatment of metastatic breast cancer.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Breast Neoplasms - Phase I
Neoplasm Metastasis - Phase II
Drug: CPG 7909
Drug: Herceptin
Phase 1/Phase 2

Verified by Pfizer October, 2008

Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov identifier: NCT00043394

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Tess Schmalbach, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site